| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 28 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.39M | $441.12M | - | |
| CEO | 890.4K | $53.16M | - | |
| CEO | 875.0K | $52.24M | - | |
| Other | 740.2K | $44.19M | - | |
| COO | 215.3K | $12.85M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE | 5,000 | $52.67 | $263,373.38 | -3.5% | - | - | |
| Jul 17, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 6,018 | $52.64 | $316,780.33 | -2.4% | - | - | |
| Jul 6, 2026 | Kunkel Lori Anne | Director | Sell | 10,000 | $50.49 | $504,903.25 | -10.0% | - | - | |
| Jun 17, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 6,018 | $43.80 | $263,577.34 | -3.6% | - | - | |
| Jun 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE | 5,000 | $43.80 | $219,016.84 | -5.9% | - | - | |
| Jun 15, 2026 | Orbimed Advisors LLC66 | 10% Owner | Sell | 281,408 | $45.02 | $12,668,988.16 | -3.6% | - | - | |
| Apr 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE | 5,000 | $47.67 | $238,352.42 | -5.7% | +5.7% | - | |
| Mar 10, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE | 40,000 | $30.07 | $1,202,637.98 | -44.4% | +14.8% | - | |
| Feb 6, 2026 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 5,000 | $29.04 | $145,219.00 | -0.7% | +36.9% | - | |
| Jan 9, 2026 | Patel Anish53 | Chief Operating Officer | Sell | 48,300 | $27.99 | $1,351,762.20 | -10.1% | +75.3% | - |